Dendreon is focused on discovering, developing and commercializing novel therapeutics to fight cancer. Our pipeline includes active cellular immunotherapy, monoclonal antibody and small molecule product candidates to treat a wide range of cancers.

Dendreon announces Interim data from phase 3 Provenge Impact Trail
Dendreon Announces Interim Data from Phase 3 PROVENGE IMPACT Trial SEATTLE, October 6, 2008 - Dendreon Corporation (Nasdaq: DNDN) announced today that it has completed the planned interim analysis
http://investor.dendreon.com/releasedetail.cfm...
Dendreon Drug Trp-P8 Dendreon Pipeline
PROMISING NEW CANCER THERAPIES ON THE HORIZON Dendreon is focused on discovering, developing and commercializing novel therapeutics to fight cancer. Our pipeline includes active cellular immunother
http://www.dendreon.com/pipeline/